Screener
Quest Diagnostics DGX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Quest Diagnostics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Quest Diagnostics’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001022079-26-000070
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Less: Net income attributable to noncontrolling interests | 14 | 14 | 26 | 29 |
| Net income attributable to Quest Diagnostics | $320 | $282 | $572 | $502 |
| Earnings per share attributable to Quest Diagnostics’ common stockholders: | ||||
| Basic | $2.88 | $2.51 | $5.15 | $4.48 |
| Diluted | $2.84 | $2.47 | $5.08 | $4.41 |
| Weighted average common shares outstanding: | ||||
| Basic | 111 | 112 | 110 | 112 |
| Diluted | 112 | 113 | 112 | 113 |
Cover / Front Matter
FAQ
- What is Quest Diagnostics's EPS (diluted)?
- Quest Diagnostics (DGX) reported EPS (diluted) of $2.84 in Q2 2026.
- How has Quest Diagnostics's EPS (diluted) changed year-over-year?
- Quest Diagnostics's EPS (diluted) increased by 15.0% year-over-year, from $2.47 to $2.84.
- What is the long-term trend for Quest Diagnostics's EPS (diluted)?
- Over 4 years (2021 to 2025), Quest Diagnostics's EPS (diluted) has grown at a -13.4% compound annual growth rate (CAGR), from $15.58 to $8.75.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Quest Diagnostics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude